151 related articles for article (PubMed ID: 28591415)
21. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma.
Tang H; Wei Q; Ge J; Jian W; Liu J; Zhong L; Fu B; Zhao T
Hum Pathol; 2013 Oct; 44(10):2167-72. PubMed ID: 23845468
[TBL] [Abstract][Full Text] [Related]
22. Risk stratification and prognostic biomarkers in relapsed Hodgkin lymphoma.
Bröckelmann PJ; von Tresckow B
Br J Haematol; 2020 Sep; 190(6):813-814. PubMed ID: 32506494
[No Abstract] [Full Text] [Related]
23. Prognostic factors in Hodgkin's lymphoma.
Zander T; Wiedenmann S; Wolf J
Ann Oncol; 2002; 13 Suppl 1():67-74. PubMed ID: 12078906
[TBL] [Abstract][Full Text] [Related]
24. [Expression of fragile histidine triad (FHIT) protein and its significance in diagnosing classical Hodgkin lymphoma].
Zhao P; Lü YL; Zhong M; Chen LH; Pu XL
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):289-91. PubMed ID: 16777001
[TBL] [Abstract][Full Text] [Related]
25. An update on disease biomarkers for Hodgkin lymphoma.
Cirillo M; Borchmann S
Expert Rev Hematol; 2020 May; 13(5):481-488. PubMed ID: 32193957
[No Abstract] [Full Text] [Related]
26. Hodgkin's lymphoma.
Tsang RW; Hodgson DC; Crump M
Curr Probl Cancer; 2006; 30(3):107-58. PubMed ID: 16740424
[No Abstract] [Full Text] [Related]
27. Utility of LRF/Pokemon and NOTCH1 protein expression in the distinction between nodular lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma.
Bohn O; Maeda T; Filatov A; Lunardi A; Pandolfi PP; Teruya-Feldstein J
Int J Surg Pathol; 2014 Feb; 22(1):6-11. PubMed ID: 24326827
[TBL] [Abstract][Full Text] [Related]
28. Hodgkin lymphoma.
Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Bello CM; Bierman PJ; Blum KA; Dabaja B; Duron Y; Forero A; Gordon LI; Hernandez-Ilizaliturri FJ; Hochberg EP; Maloney DG; Mansur D; Mauch PM; Metzger M; Moore JO; Morgan D; Moskowitz CH; Poppe M; Pro B; Weiss L; Winter JN; Yahalom J;
J Natl Compr Canc Netw; 2011 Sep; 9(9):1020-58. PubMed ID: 21917626
[No Abstract] [Full Text] [Related]
29. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas.
Kondratiev S; Duraisamy S; Unitt CL; Green MR; Pinkus GS; Shipp MA; Kutok JL; Drapkin RI; Rodig SJ
Am J Surg Pathol; 2011 Oct; 35(10):1531-9. PubMed ID: 21921781
[TBL] [Abstract][Full Text] [Related]
30. The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma.
Aladily TN; Mansour A; Alsughayer A; Sughayer M; Medeiros LJ
Ann Diagn Pathol; 2019 Jun; 40():72-76. PubMed ID: 31075666
[TBL] [Abstract][Full Text] [Related]
31. [Diagnosis and treatment of classical Hodgkin lymphoma].
Nagai H
Nihon Rinsho; 2012 Apr; 70 Suppl 2():568-76. PubMed ID: 23134017
[No Abstract] [Full Text] [Related]
32. [Hodgkin lymphoma (Hodgkin disease)].
Naumann UK; Käser L; Vetter W
Praxis (Bern 1994); 2006 Nov; 95(44):1697-703; quiz 1704, 1706. PubMed ID: 17111877
[No Abstract] [Full Text] [Related]
33. Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases.
Canioni D; Deau-Fischer B; Taupin P; Ribrag V; Delarue R; Bosq J; Rubio MT; Roux D; Vasiliu V; Varet B; Brousse N; Hermine O
PLoS One; 2009 Jul; 4(7):e6341. PubMed ID: 19623262
[TBL] [Abstract][Full Text] [Related]
34. [PROGNOSTIC RISK FACTORS FOR NEWLY DIAGNOSED PATIENTS WITH ADVANCED STAGES CLASSICAL HODGKIN'S LYMPHOMA].
Novosad OI; Kriachok IA; Grabovyy OM; Antonuk SA
Lik Sprava; 2014; (9-10):88-94. PubMed ID: 26492782
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type.
Asano N; Kinoshita T; Tamaru J; Ohshima K; Yoshino T; Niitsu N; Tsukamoto N; Hirabayashi K; Izutsu K; Taniwaki M; Morishima Y; Nakamura S
Haematologica; 2011 Nov; 96(11):1636-43. PubMed ID: 21859738
[TBL] [Abstract][Full Text] [Related]
36. Hodgkin lymphoma and the impact of age.
Armitage JO
Oncology (Williston Park); 2008 Nov; 22(12):1379, 1385. PubMed ID: 19322947
[No Abstract] [Full Text] [Related]
37. Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma.
McKay P; Fielding P; Gallop-Evans E; Hall GW; Lambert J; Leach M; Marafioti T; McNamara C;
Br J Haematol; 2016 Jan; 172(1):32-43. PubMed ID: 26538004
[No Abstract] [Full Text] [Related]
38. Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases.
Went P; Tzankov A; Schwaller J; Passweg J; Roosnek E; Huard B
Exp Hematol; 2008 May; 36(5):533-4. PubMed ID: 18439487
[No Abstract] [Full Text] [Related]
39. [Standard therapy and research questions in Hodgkin lymphoma].
Suzuki T
Rinsho Ketsueki; 2012 Oct; 53(10):1615-23. PubMed ID: 23037734
[No Abstract] [Full Text] [Related]
40. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment.
Hsi ED
Leuk Lymphoma; 2008 Sep; 49(9):1668-80. PubMed ID: 18798102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
